Jim Simons’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.23M | Buy |
578,024
+281,574
| +95% | +$1.11M | ﹤0.01% | 1842 |
|
|
2025
Q4 | $1.17M | Buy |
296,450
+34,000
| +13% | +$150K | ﹤0.01% | 2190 |
|
|
2025
Q3 | $1.23M | Sell |
262,450
-129,650
| -33% | -$469K | ﹤0.01% | 2380 |
|
|
2025
Q2 | $1.22M | Buy |
392,100
+271,900
| +226% | +$877K | ﹤0.01% | 2402 |
|
|
2025
Q1 | $406K | Sell |
120,200
-19,700
| -14% | -$92K | ﹤0.01% | 2822 |
|
|
2024
Q4 | $793K | Sell |
139,900
-138,767
| -50% | -$895K | ﹤0.01% | 2612 |
|
|
2024
Q3 | $1.63M | Buy |
278,667
+215,467
| +341% | +$1.57M | ﹤0.01% | 2152 |
|
|
2024
Q2 | $500K | Sell |
63,200
-64,900
| -51% | -$544K | ﹤0.01% | 2690 |
|
|
2024
Q1 | $1.19M | Sell |
128,100
-55,000
| -30% | -$464K | ﹤0.01% | 2380 |
|
|
2023
Q4 | $1.54M | Sell |
183,100
-220,500
| -55% | -$1.6M | ﹤0.01% | 2107 |
|
|
2023
Q3 | $3.13M | Buy |
403,600
+90,600
| +29% | +$827K | 0.01% | 1580 |
|
|
2023
Q2 | $3.58M | Buy |
313,000
+180,700
| +137% | +$1.87M | 0.01% | 1614 |
|
|
2023
Q1 | $1.02M | Buy |
132,300
+13,000
| +11% | +$103K | ﹤0.01% | 2472 |
|
|
2022
Q4 | $728K | Buy |
119,300
+2,500
| +2% | +$14.2K | ﹤0.01% | 2717 |
|
|
2022
Q3 | $691K | Buy |
116,800
+22,500
| +24% | +$144K | ﹤0.01% | 2722 |
|
|
2022
Q2 | $557K | Buy |
+94,300
| New | +$637K | ﹤0.01% | 3103 |
|
|
2022
Q1 | – | Sell |
-52,617
| Closed | -$143K | – | 4515 |
|
|
2021
Q4 | $143K | Sell |
52,617
-262,510
| -83% | -$896K | ﹤0.01% | 3613 |
|
|
2021
Q3 | $829K | Sell |
315,127
-75,263
| -19% | -$244K | ﹤0.01% | 2649 |
|
|
2021
Q2 | $1.61M | Sell |
390,390
-35,011
| -8% | -$159K | ﹤0.01% | 2400 |
|
|
2021
Q1 | $2M | Sell |
425,401
-404,858
| -49% | -$2.76M | ﹤0.01% | 2227 |
|
|
2020
Q4 | $5.94M | Buy |
830,259
+4,058
| +0.5% | +$39K | 0.01% | 1485 |
|
|
2020
Q3 | $8.82M | Sell |
826,201
-19,479
| -2% | -$229K | 0.01% | 1229 |
|
|
2020
Q2 | $10.7M | Sell |
845,680
-197,121
| -19% | -$2.29M | 0.01% | 1177 |
|
|
2020
Q1 | $9.54M | Sell |
1,042,801
-202,700
| -16% | -$2.33M | 0.01% | 1194 |
|
|
2019
Q4 | $17.4M | Buy |
1,245,501
+172,600
| +16% | +$2.51M | 0.01% | 1080 |
|
|
2019
Q3 | $18.5M | Buy |
1,072,901
+343,100
| +47% | +$7.2M | 0.02% | 1003 |
|
|
2019
Q2 | $19.9M | Buy |
729,801
+237,500
| +48% | +$5.43M | 0.02% | 970 |
|
|
2019
Q1 | $9.42M | Buy |
492,301
+60,000
| +14% | +$782K | 0.01% | 1417 |
|
|
2018
Q4 | $4.06M | Buy |
432,301
+356,901
| +473% | +$4.58M | ﹤0.01% | 1851 |
|
|
2018
Q3 | $1.43M | Sell |
75,400
-20,200
| -21% | -$388K | ﹤0.01% | 2453 |
|
|
2018
Q2 | $1.87M | Sell |
95,600
-115,965
| -55% | -$2.29M | ﹤0.01% | 2293 |
|
|
2018
Q1 | $3.98M | Buy |
+211,565
| New | +$4.57M | ﹤0.01% | 1964 |
|
|
2017
Q4 | – | Sell |
-33,300
| Closed | -$686K | – | 3514 |
|
|
2017
Q3 | $686K | Buy |
33,300
+22,800
| +217% | +$257K | ﹤0.01% | 2707 |
|
|
2017
Q2 | $94K | Buy |
+10,500
| New | +$106K | ﹤0.01% | 3089 |
|
Other funds holding VYGR
AC
VPC
VCM
OM
EAM
Jim Simons's VYGR Position: Q1 2026 in Review
Jim Simons increased its Voyager Therapeutics (VYGR) stake by 95% in Q1 2026, buying an estimated $1.11M and bringing the position to 578,024 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1842.
Jim Simons first reported a position in VYGR in Q2 2017 and has held it in 34 quarters since. The position peaked at $19.9M in Q2 2019. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.
- Jim Simons held 578,024 shares of Voyager Therapeutics worth $2.23M as of Q1 2026.
- Jim Simons bought 281,574 Voyager Therapeutics shares in Q1 2026, an estimated $1.11M.
- Voyager Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #1842 holding.
- Jim Simons first reported a position in Voyager Therapeutics in Q2 2017 and has held it in 34 quarters since.
- Jim Simons's Voyager Therapeutics position peaked at $19.9M in Q2 2019.
- 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.